Hospital Authority

This program comprises a fixed-dose combination of three oral small-molecule antimycobacterial agents—isoniazid, rifampin, and pyrazinamide—sponsored by Hospital Authority, Hong Kong, with internal code 201010025M. The combination is indicated for hepatitis treatment and holds approved regulatory status as of the latest milestone dated 27 December 2012. The program remains active. Mechanism of action and specific molecular targets are not yet disclosed. The combination represents a repurposing of established tuberculosis therapeutics into the hepatitis indication. No partner or licensing arrangement is documented. The program is supported by clinical trial NCT01395654. Peak sales projections and consensus positioning are not yet disclosed.

Hepatitis remains a significant global health burden with substantial morbidity and mortality. The approved status of this isoniazid–rifampin–pyrazinamide combination addresses treatment options within a competitive landscape dominated by antivirals, interferons, and vaccines. The competitive environment includes established agents such as peginterferon alfa-2a (Hoffmann-La Roche), adefovir dipivoxil (GlaxoSmithKline), tenofovir disoproxil fumarate (Gilead Sciences), and entecavir, as well as hepatitis B vaccines from multiple manufacturers. Hospital Authority's development of this combination suggests clinical utility in specific hepatitis patient populations, though the precise therapeutic niche relative to modern direct-acting antivirals and nucleos(t)ide reverse transcriptase inhibitors remains undisclosed. The program's active status and 2012 milestone indicate sustained institutional commitment. Commercial significance depends on efficacy, safety, tolerability, and cost positioning relative to established therapies, none of which are detailed in available disclosures.

Drug Class: Fixed-dose combination of antimycobacterial small molecules repurposed for hepatitis indication.

• Modality: Small-molecule oral combination therapy
• Components: Isoniazid, rifampin, pyrazinamide
• Route of Administration: Oral
• Mechanism of Action: Not yet disclosed
• Molecular Target: Not yet disclosed
• Regulatory Status (Pyrazinamide component): FDA-approved via ANDA applications (ANDA080157, ANDA081319, ANDA212541) with multiple generic sponsors including Hikma, Macleods Pharmaceuticals, and Novitium Pharma
• Related Therapies: Peginterferon alfa-2a, peginterferon alfa-2b, adefovir dipivoxil, tenofovir disoproxil fumarate, entecavir, hepatitis B vaccines
• Patent Status: Not yet disclosed

Regulatory Status: The program holds approved status as of 27 December 2012 and remains active. Jurisdiction-specific approval details (FDA, EMA, PMDA, NMPA) are not yet disclosed. The pyrazinamide component holds FDA approval via multiple ANDA applications (ANDA080157, ANDA081319, ANDA212541) with generic sponsors Hikma, Macleods Pharmaceuticals, and Novitium Pharma, indicating established regulatory precedent for this component in the United States. Approval pathway, regulatory agency, and geographic scope for the fixed-dose combination in the hepatitis indication are not yet disclosed.

Strategic Implications: Hospital Authority's sponsorship and active status suggest institutional confidence in this combination's clinical utility for hepatitis. The 2012 milestone and absence of subsequent updates may indicate stable commercial deployment or dormant development status. Repurposing of established antimycobacterial agents reduces development risk and regulatory burden relative to novel entities.

Competitive Implications: The combination enters a mature market dominated by antivirals, interferons, and vaccines with established efficacy and safety profiles. Differentiation likely depends on efficacy in specific patient subpopulations (e.g., treatment-experienced, genotype-specific, or coinfection scenarios), cost advantage, or tolerability profile—none of which are disclosed. The program does not appear to target hepatitis C direct-acting antivirals or modern hepatitis B nucleos(t)ide reverse transcriptase inhibitors as primary competitors.

Future Catalysts: Publication of NCT01395654 results, regulatory approvals in additional jurisdictions, label expansions, and commercial uptake data would clarify clinical positioning and market relevance. Absence of disclosed milestones since 2012 suggests limited recent development activity or communication.